Περιγραφή
This greatly expanded third edition provides a comprehensive overview of clinical psychopharmacology, incorporating the major advances in the field since the previous edition’s publication. Renowned experts from psychiatry, pharmacy, and nursing have integrated basic science, psychopharmacology, and clinical practice throughout the book in order to provide a thorough basis for prescribing. It covers all key psychiatric drugs and disorders and includes the latest data on efficacy, safety and tolerability. Adopting a pragmatic approach to drug nomenclature, both Neuroscience-based Nomenclature (NbN) and older generic terminology are included in the text reflecting that clinicians are likely to use both systems. Many chapters refer to current National Institute of Health and Care Excellence (NICE) guidelines, making this a crucial resource. Edited by leading authorities in the field, Professor Peter M. Haddad and Professor David J. Nutt, Seminars in Clinical Psychopharmacology emphasises evidence-based prescribing with the aim of achieving better clinical outcomes for patients.
- Part of the iconic College Seminars Series, developed by the Royal College of Psychiatrists
- Integration of basic science, psychopharmacology, and clinical practice gives readers a solid grounding in the basics of the field and provides a thorough basis for prescribing
- Uses Neuroscience-based Nomenclature (NbN) in line with current policies of most psychopharmacology journals, but older terminology still appears in recognition of clinicians who will likely use both
- Authors come from a range of professions, covering psychiatrists, preclinical scientists, pharmacists, and nurses, appealing to a wide audience
Περιεχόμενα
List of contributors
Foreword Peter Tyrer
Preface
Editor’s note on nomenclature
Neuroscience-based nomenclature glossary
List of abbreviations
Part I. Basic Science and General Principles:
1. A brief history of psychopharmacology Peter M. Haddad, David J. Nutt and Richard Green
2. Psychiatric drug discovery and development Mohammed Shahid, Joanna C. Neill and John Hutchison
3. Neurotransmission and mechanisms of drug action Brian E. Leonard
4. Pharmacodynamics and pharmacokinetics Stuart Gill-Banham and David Taylor
5. Pharmacogenomics and psychopharmacology Diego L. Lapetina, Esther H. Yang, Beatriz C. Henriques and Katherine J. Aitchison
6. Good clinical practice in psychopharmacology Peter M. Haddad and Thomas R. E. Barnes
Part II. Psychopharmacology of the Main Psychotropic Drug Groups:
7. Drugs to treat depression Patrick McLaughlin and Anthony Cleare
8. Drugs to treat anxiety and insomnia David S. Baldwin and Nathan Huneke
9. Drugs to treat schizophrenia and psychosis (dopamine antagonists and partial agonists other than clozapine) Robert McCutcheon, Stephen J. Kaar and Oliver D. Howes
10. Clozapine Richard Drake
11. Lithium Allan H. Young and Dilveer S. Sually
12. Anticonvulsants for mental disorders: valproate, lamotrigine, carbamazepine, and oxcarbazepine Peter S. Talbot
13. Drugs to treat attention deficit hyperactivity disorder (ADHD) Ulrich Müller-Sedgwick and Jane A. Sedgwick-Müller
14. Drugs to treat dementia Ross Dunne and Alistair Burns
15. Drugs to treat substance use disorder (SUD) Julia Sinclair and Lesley Peters
16. ECT and neuromodulation therapies David Christmas and Keith Matthews
Part III. Specific Therapeutic Areas:
17. Drug treatment in childhood and adolescence David Coghill and Nicoletta Adamo
18. Drug treatment in later life Simon J. C. Davies
19. Prescribing in pregnancy and lactation Angelika Wieck and Ian Jones
20. The clinical management of acute disturbance including rapid tranquilisation Faisil Sethi, Caroline Parker, Aileen O’Brien and Maxine X. Patel
21. Antipsychotics, weight gain and metabolic risk Stephen J. Cooper and Gavin P. Reynolds
Index.
